Univariate outcomes after transplantation
| Outcome event . | n . | MAC (n = 165) . | n . | RIC (n = 143) . | n . | NMAC (n = 88) . | P* . |
|---|---|---|---|---|---|---|---|
| Probability (95% CI) . | Probability (95% CI) . | Probability (95% CI) . | |||||
| Time to ANC ≥ 0.5 × 109/L | 164 | 143 | 88 | ||||
| 28 d | 86 (80-90) | 96 (90-98) | 92 (83-96) | .012 | |||
| 100 d | 88 (82-92) | 99 (94-100) | 97 (90-99) | < .001 | |||
| aGVHD (II-IV) | 164 | 143 | 88 | ||||
| 100 d | 43 (36-51) | 43 (35-51) | 44 (34-55) | .970 | |||
| cGVHD | 163 | 137 | 88 | ||||
| 1 y | 35 (28-43) | 39 (31-47) | 33 (24-43) | .641 | |||
| 3 y | 37 (30-45) | 41 (32-49) | 37 (27-47) | .794 | |||
| 5 y | 37 (30-45) | 42 (34-51) | 37 (27-47) | .605 | |||
| NRM | 163 | 142 | 86 | ||||
| 100 d | 32 (25-39) | 24 (17-31) | 17 (10-26) | .029 | |||
| 1 y | 47 (39-54) | 31 (24-39) | 29 (20-39) | .004 | |||
| 3 y | 55 (47-63) | 42 (34-50) | 34 (24-45) | .003 | |||
| 5 y | 56 (48-64) | 47 (38-56) | 36 (26-46) | .007 | |||
| Relapse/progression | 163 | 142 | 86 | ||||
| 1 y | 23 (17-30) | 32 (25-40) | 37 (27-48) | .043 | |||
| 3 y | 26 (19-33) | 35 (27-43) | 38 (28-49) | .078 | |||
| 5 y | 26 (19-33) | 38 (30-46) | 40 (30-50) | .031 | |||
| PFS | 163 | 142 | 86 | ||||
| 1 y | 30 (23-38) | 37 (29-45) | 34 (24-44) | .487 | |||
| 3 y | 19 (13-25) | 23 (16-31) | 27 (18-37) | .309 | |||
| 5 y | 18 (12-24) | 15 (9-23) | 25 (16-34) | .309 | |||
| OS | 165 | 143 | 88 | ||||
| 1 y | 38 (31-45) | 46 (37-54) | 45 (35-56) | .315 | |||
| 3 y | 21 (15-28) | 27 (20-35) | 29 (20-39) | .302 | |||
| 5 y | 18 (12-25) | 20 (13-29) | 26 (17-36) | .365 |
| Outcome event . | n . | MAC (n = 165) . | n . | RIC (n = 143) . | n . | NMAC (n = 88) . | P* . |
|---|---|---|---|---|---|---|---|
| Probability (95% CI) . | Probability (95% CI) . | Probability (95% CI) . | |||||
| Time to ANC ≥ 0.5 × 109/L | 164 | 143 | 88 | ||||
| 28 d | 86 (80-90) | 96 (90-98) | 92 (83-96) | .012 | |||
| 100 d | 88 (82-92) | 99 (94-100) | 97 (90-99) | < .001 | |||
| aGVHD (II-IV) | 164 | 143 | 88 | ||||
| 100 d | 43 (36-51) | 43 (35-51) | 44 (34-55) | .970 | |||
| cGVHD | 163 | 137 | 88 | ||||
| 1 y | 35 (28-43) | 39 (31-47) | 33 (24-43) | .641 | |||
| 3 y | 37 (30-45) | 41 (32-49) | 37 (27-47) | .794 | |||
| 5 y | 37 (30-45) | 42 (34-51) | 37 (27-47) | .605 | |||
| NRM | 163 | 142 | 86 | ||||
| 100 d | 32 (25-39) | 24 (17-31) | 17 (10-26) | .029 | |||
| 1 y | 47 (39-54) | 31 (24-39) | 29 (20-39) | .004 | |||
| 3 y | 55 (47-63) | 42 (34-50) | 34 (24-45) | .003 | |||
| 5 y | 56 (48-64) | 47 (38-56) | 36 (26-46) | .007 | |||
| Relapse/progression | 163 | 142 | 86 | ||||
| 1 y | 23 (17-30) | 32 (25-40) | 37 (27-48) | .043 | |||
| 3 y | 26 (19-33) | 35 (27-43) | 38 (28-49) | .078 | |||
| 5 y | 26 (19-33) | 38 (30-46) | 40 (30-50) | .031 | |||
| PFS | 163 | 142 | 86 | ||||
| 1 y | 30 (23-38) | 37 (29-45) | 34 (24-44) | .487 | |||
| 3 y | 19 (13-25) | 23 (16-31) | 27 (18-37) | .309 | |||
| 5 y | 18 (12-24) | 15 (9-23) | 25 (16-34) | .309 | |||
| OS | 165 | 143 | 88 | ||||
| 1 y | 38 (31-45) | 46 (37-54) | 45 (35-56) | .315 | |||
| 3 y | 21 (15-28) | 27 (20-35) | 29 (20-39) | .302 | |||
| 5 y | 18 (12-25) | 20 (13-29) | 26 (17-36) | .365 |
n indicates number of patients; and ANC, absolute neutrophil count.
Probabilities of neutrophil recovery, platelet recovery, aGVHD, cGVHD, NRM, and progression/relapse were calculated using the cumulative incidence estimate. PFS and OS were calculated using the Kaplan-Meier product limit estimate.